Leslie A Fecher

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. doi request reprint The MAPK pathway in melanoma
    Leslie A Fecher
    University of Pennsylvania, Division of Hematology and Oncology, Department of Medicine, The Abramson Cancer Center, Philadelphia, Pennsylvania 19104, USA
    Curr Opin Oncol 20:183-9. 2008
  2. ncbi request reprint Where are we with adjuvant therapy of stage III and IV melanoma in 2009?
    Leslie A Fecher
    Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
    J Natl Compr Canc Netw 7:295-304. 2009
  3. doi request reprint Drug targeting of oncogenic pathways in melanoma
    Leslie A Fecher
    Department of Medicine, Division of Hematology and Oncology, Abramson Cancer Center, University of Pennsylvania, 3400 Spruce Street, 16 Penn Tower, Philadelphia, PA 19104, USA
    Hematol Oncol Clin North Am 23:599-618, x. 2009
  4. doi request reprint Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study
    Emily Y Chu
    Department of Dermatology, Hospital of University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Am Acad Dermatol 67:1265-72. 2012
  5. pmc Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers
    Erica L Carpenter
    Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Clin Cancer Res 15:4277-87. 2009
  6. ncbi request reprint Toward a molecular classification of melanoma
    Leslie A Fecher
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, USA
    J Clin Oncol 25:1606-20. 2007
  7. doi request reprint Effectively targeting BRAF in melanoma: a formidable challenge
    Leslie A Fecher
    Pigment Cell Melanoma Res 21:410-1. 2008

Collaborators

Detail Information

Publications7

  1. doi request reprint The MAPK pathway in melanoma
    Leslie A Fecher
    University of Pennsylvania, Division of Hematology and Oncology, Department of Medicine, The Abramson Cancer Center, Philadelphia, Pennsylvania 19104, USA
    Curr Opin Oncol 20:183-9. 2008
    ..Several therapeutic agents directed against this pathway are in development. This review summarizes current understanding of the MAPK pathway in melanoma biology and therapeutic strategies...
  2. ncbi request reprint Where are we with adjuvant therapy of stage III and IV melanoma in 2009?
    Leslie A Fecher
    Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
    J Natl Compr Canc Netw 7:295-304. 2009
    ..This article explores the factors to consider when individualizing care within the scope of these guidelines...
  3. doi request reprint Drug targeting of oncogenic pathways in melanoma
    Leslie A Fecher
    Department of Medicine, Division of Hematology and Oncology, Abramson Cancer Center, University of Pennsylvania, 3400 Spruce Street, 16 Penn Tower, Philadelphia, PA 19104, USA
    Hematol Oncol Clin North Am 23:599-618, x. 2009
    ..The targeting of certain cellular processes, downstream of the common genetic alterations, for which the issues of target and drug validation are somewhat distinct, are also highlighted...
  4. doi request reprint Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study
    Emily Y Chu
    Department of Dermatology, Hospital of University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Am Acad Dermatol 67:1265-72. 2012
    ..Similar to the broad-spectrum RAF inhibitor sorafenib, vemurafenib induces development of squamous cell carcinomas and keratoacanthomas as a side effect of therapy...
  5. pmc Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers
    Erica L Carpenter
    Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Clin Cancer Res 15:4277-87. 2009
    ..This study aimed to investigate whether B-cell physiology was altered in the presence of melanoma and other cancers...
  6. ncbi request reprint Toward a molecular classification of melanoma
    Leslie A Fecher
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, USA
    J Clin Oncol 25:1606-20. 2007
    ..We eagerly anticipate rationally designed melanoma therapies based on such a classification scheme and the associated improvements in patient outcomes...
  7. doi request reprint Effectively targeting BRAF in melanoma: a formidable challenge
    Leslie A Fecher
    Pigment Cell Melanoma Res 21:410-1. 2008